nach oben

27.03.2024 | Original Article

Effectiveness of calcimimetics on fractures in dialysis patients with secondary hyperparathyroidism: meta-analysis of randomized trials

verfasst von: Takuya Wakamatsu, Suguru Yamamoto, Koji Matsuo, Masatomo Taniguchi, Takayuki Hamano, Masafumi Fukagawa, Junichiro James Kazama

Erschienen in: Journal of Bone and Mineral Metabolism

Einloggen, um Zugang zu erhalten

Abstract

Introduction

This study aimed to assess the effectiveness of calcimimetics in reducing the risk of fractures in dialysis patients with secondary hyperparathyroidism (SHPT).

Material and methods

A comprehensive literature search was conducted using PubMed, Embase, and Cochrane Library for articles published through December 9, 2023. The quality of each trial was evaluated using the Cochrane Collaboration tool. Meta-analysis was performed using a random-effects model, and effect measures across studies were synthesized. The risk ratio (RR) and 95% confidence interval (CI) were used to quantify the risk of fracture.

Results

We identified seven studies involving 6481 dialysis patients with SHPT. The administration of calcimimetics reduced fracture incidence compared to placebo or conventional treatment (RR: 0.50, 95% CI 0.29–0.88, p = 0.02). Calcimimetics demonstrated a low number needed to treat (NNT) to prevent an incident fracture (NNT: 47).

Conclusion

The use of calcimimetics offers a significant benefit in reducing the risk of fractures in patients undergoing dialysis with SHPT.

Nur mit Berechtigung zugänglich

Wakasugi M, Kazama JJ, Taniguchi M, Wada A, Iseki K, Tsubakihara Y, Narita I (2013) Increased risk of hip fracture among Japanese hemodialysis patients. J Bone Miner Metab 31:315–321. https://doi.org/10.1007/s00774-012-0411-zCrossRefPubMed

Alem AM, Sherrard DJ, Gillen DL, Weiss NS, Beresford SA, Heckbert SR, Wong C, Stehman-Breen C (2000) Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 58:396–399. https://doi.org/10.1046/j.1523-1755.2000.00178.xCrossRefPubMed

Coco M, Rush H (2000) Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 36:1115–1121. https://doi.org/10.1053/ajkd.2000.19812CrossRefPubMed

Tentori F, McCullough K, Kilpatrick RD, Bradbury BD, Robinson BM, Kerr PG, Pisoni RL (2014) High rates of death and hospitalization follow bone fracture among hemodialysis patients. Kidney Int 85:166–173. https://doi.org/10.1038/ki.2013.279CrossRefPubMed

Tentori F, Wang M, Bieber BA, Karaboyas A, Li Y, Jacobson SH, Andreucci VE, Fukagawa M, Frimat L, Mendelssohn DC, Port FK, Pisoni RL, Robinson BM (2015) Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Clin J Am Soc Nephrol: CJASN 10:98–109. https://doi.org/10.2215/CJN.12941213CrossRefPubMed

Taniguchi M, Fukagawa M, Fujii N, Hamano T, Shoji T, Yokoyama K, Nakai S, Shigematsu T, Iseki K, Tsubakihara Y, Committee of Renal Data Registry of the Japanese Society for Dialysis T (2013) Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Ther Apher Dial: Off Peer-Rev J Int Soc Apher Jpn Soc Apher Jan Soc Dial Ther 17:228. https://doi.org/10.1111/1744-9987.12030CrossRef

Block GA, Kilpatrick RD, Lowe KA, Wang W, Danese MD (2013) CKD-mineral and bone disorder and risk of death and cardiovascular hospitalization in patients on hemodialysis. Clin J Am Soc Nephrol: CJASN 8:2132–2140. https://doi.org/10.2215/CJN.04260413CrossRefPubMedPubMedCentral

Fernandez-Martin JL, Martinez-Camblor P, Dionisi MP, Floege J, Ketteler M, London G, Locatelli F, Gorriz JL, Rutkowski B, Ferreira A, Bos WJ, Covic A, Rodriguez-Garcia M, Sanchez JE, Rodriguez-Puyol D, Cannata-Andia JB, group C, (2015) Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study. Nephrol, Dial, Transplant : Off Publ Eur Dial Transplant Assoc - Eur Ren Assoc 30:1542–1551. https://doi.org/10.1093/ndt/gfv099CrossRef

Wakasugi M, Kazama JJ, Kikuchi K, Yasuda K, Wada A, Hamano T, Masakane I, Narita I (2019) Hemodialysis product and hip fracture in hemodialysis patients: a nationwide cohort study in Japan. Ther Apher Dial: Off Peer-Rev J Int Soc Apher, Jpn Soc Apher, Jpn Society Dial Ther 23:507–517. https://doi.org/10.1111/1744-9987.12807CrossRef

10.

Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-Gresham JL, Mason N, Prutz KG, Young EW, Pisoni RL (2006) Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 70:1358–1366. https://doi.org/10.1038/sj.ki.5001754CrossRefPubMed

11.

Custodio MR, Koike MK, Neves KR, dos Reis LM, Graciolli FG, Neves CL, Batista DG, Magalhaes AO, Hawlitschek P, Oliveira IB, Dominguez WV, Moyses RM, Jorgetti V (2012) Parathyroid hormone and phosphorus overload in uremia: impact on cardiovascular system. Nephrol, Dial, Transplant: Off Publ Eur Dial Transplant Assoc – Eur Ren Assoc 27:1437–1445. https://doi.org/10.1093/ndt/gfr447CrossRef

12.

Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM et al (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1516–1525. https://doi.org/10.1056/NEJMoa031633CrossRefPubMed

13.

Investigators ET, Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS (2012) Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367:2482–2494. https://doi.org/10.1056/NEJMoa1205624CrossRef

14.

Diaz-Tocados JM, Rodriguez-Ortiz ME, Almaden Y, Pineda C, Martinez-Moreno JM et al (2019) Calcimimetics maintain bone turnover in uremic rats despite the concomitant decrease in parathyroid hormone concentration. Kidney Int 95:1064–1078. https://doi.org/10.1016/j.kint.2018.12.015CrossRefPubMed

15.

Koiwa F, Tokunaga S, Asada S, Endo Y, Fukagawa M, Akizawa T (2021) Efficacy of evocalcet in previously cinacalcet-treated secondary hyperparathyroidism patients. Kidney Int Rep 6:2830–2839. https://doi.org/10.1016/j.ekir.2021.08.020CrossRefPubMedPubMedCentral

16.

Block GA, Bushinsky DA, Cheng S, Cunningham J, Dehmel B, Drueke TB, Ketteler M, Kewalramani R, Martin KJ, Moe SM, Patel UD, Silver J, Sun Y, Wang H, Chertow GM (2017) Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial. JAMA 317:156–164. https://doi.org/10.1001/jama.2016.19468CrossRefPubMed

17.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https://doi.org/10.1136/bmj.n71CrossRefPubMedPubMedCentral

18.

Moe SM, Abdalla S, Chertow GM, Parfrey PS, Block GA, Correa-Rotter R, Floege J, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Dehmel B, Goodman WG, Drueke TB, Evaluation of Cinacalcet HTtLCETI (2015) Effects of cinacalcet on fracture events in patients receiving hemodialysis: the evolve trial. J Am Soc Nephrol 26:1466–1475. https://doi.org/10.1681/ASN.2014040414CrossRefPubMed

19.

Kazama JJ, Koiwa F, Yokoyama K, Fukagawa M, Asano K, Honda D, Akizawa T (2022) First-in-patient phase i/ii study of upacicalcet in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: pharmacokinetic and pharmacodynamic properties. Clin Pharmacokinet 61:1271–1284. https://doi.org/10.1007/s40262-022-01139-wCrossRefPubMedPubMedCentral

20.

Cunningham J, Danese M, Olson K, Klassen P, Chertow GM (2005) Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 68:1793–1800. https://doi.org/10.1111/j.1523-1755.2005.00596.xCrossRefPubMed

21.

Block GA, Chertow GM, Sullivan JT, Deng H, Mather O, Tomlin H, Serenko M (2019) An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism. PLoS ONE 14:e0213774. https://doi.org/10.1371/journal.pone.0213774CrossRefPubMedPubMedCentral

22.

Shigematsu T, Koiwa F, Isaka Y, Fukagawa M, Hagita K, Watanabe YS, Honda D, Akizawa T (2023) Efficacy and safety of upacicalcet in hemodialysis patients with secondary hyperparathyroidism: a randomized placebo-controlled trial. Clin J Am Soc Nephrol : CJASN 18:1300–1309. https://doi.org/10.2215/CJN.0000000000000253CrossRefPubMed

23.

Itano Y, Kato S, Tsuboi M, Kasuga H, Tsuruta Y, Sato F, Hishida M, Ishimoto T, Kosugi T, Ando M, Kuwatsuka Y, Maruyama S (2020) A prospective, randomized clinical trial of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism (the DUET trial). Kidney Int Rep 5:2168–2177. https://doi.org/10.1016/j.ekir.2020.09.010CrossRefPubMedPubMedCentral

24.

El-Shafey EM, Alsahow AE, Alsaran K, Sabry AA, Atia M (2011) Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients. Ther Apher Dial: Off Peer-Rev J Int Soc Apher, Jpn Soc Apher, Jpn Soc Dial Ther 15:547–555. https://doi.org/10.1111/j.1744-9987.2011.00994.xCrossRef

25.

Yeung WG, Palmer SC, Strippoli GFM, Talbot B, Shah N, Hawley CM, Toussaint ND, Badve SV (2023) Vitamin D therapy in adults with ckd: a systematic review and meta-analysis. Am J Kidney Dis. https://doi.org/10.1053/j.ajkd.2023.04.003CrossRefPubMed

26.

Komaba H, Zhao J, Karaboyas A, Yamamoto S, Dasgupta I, Hassan M, Zuo L, Christensson A, Combe C, Robinson BM, Fukagawa M (2023) Active vitamin D use and fractures in hemodialysis patients: results from the international DOPPS. J Bone Miner Res: Off J Am Soc Bone Miner Res 38:1577–1585. https://doi.org/10.1002/jbmr.4913CrossRef

27.

Rudser KD, de Boer IH, Dooley A, Young B, Kestenbaum B (2007) Fracture risk after parathyroidectomy among chronic hemodialysis patients. J Am Soc Nephrol 18:2401–2407. https://doi.org/10.1681/ASN.2007010022CrossRefPubMed

28.

Ishani A, Liu J, Wetmore JB, Lowe KA, Do T, Bradbury BD, Block GA, Collins AJ (2015) Clinical outcomes after parathyroidectomy in a nationwide cohort of patients on hemodialysis. Clin J Am Soc Nephrol : CJASN 10:90–97. https://doi.org/10.2215/CJN.03520414CrossRefPubMed

29.

Behets GJ, Spasovski G, Sterling LR, Goodman WG, Spiegel DM, De Broe ME, D’Haese PC (2015) Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism. Kidney Int 87:846–856. https://doi.org/10.1038/ki.2014.349CrossRefPubMed

30.

Khairallah P, Cherasard J, Sung J, Agarwal S, Aponte MA, Bucovsky M, Fusaro M, Silberzweig J, Frumkin GN, El Hachem K, Schulman L, McMahon D, Allen MR, Metzger CE, Surowiec RK, Wallace J, Nickolas TL (2023) Changes in bone quality after treatment with etelcalcetide. Clin J Am Soc Nephrol : CJASN. https://doi.org/10.2215/CJN.0000000000000254CrossRefPubMed

31.

Li X, Yu L, Asuncion F, Grisanti M, Alexander S, Hensley K, Han CY, Niu QT, Dwyer D, Villasenor K, Stolina M, Dean C Jr, Ominsky MS, Ke HZ, Tomlinson JE, Richards WG (2017) Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism. Bone 105:163–172. https://doi.org/10.1016/j.bone.2017.08.026CrossRefPubMed

32.

Al-Dujaili SA, Koh AJ, Dang M, Mi X, Chang W, Ma PX, McCauley LK (2016) Calcium sensing receptor function supports osteoblast survival and acts as a co-factor in pth anabolic actions in bone. J Cell Biochem 117:1556–1567. https://doi.org/10.1002/jcb.25447CrossRefPubMedPubMedCentral

33.

Disease K (2011) Improving global outcomes ckdmbduwg (2017) kdigo 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 7:1–59. https://doi.org/10.1016/j.kisu.2017.04.001CrossRef

34.

Fukagawa M, Yokoyama K, Koiwa F, Taniguchi M, Shoji T et al (2013) Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder (in eng). Ther Apher And Dial: Off Peer-Rev J Int Soc Apher, Jpn Soc Apher, Jpn Soc Dial Ther 17:247–288. https://doi.org/10.1111/1744-9987.12058CrossRef

35.

Harbord RM, Egger M, Sterne JA (2006) A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med 25:3443–3457. https://doi.org/10.1002/sim.2380CrossRefPubMed

Titel: Effectiveness of calcimimetics on fractures in dialysis patients with secondary hyperparathyroidism: meta-analysis of randomized trials
verfasst von: Takuya Wakamatsu
Suguru Yamamoto
Koji Matsuo
Masatomo Taniguchi
Takayuki Hamano
Masafumi Fukagawa
Junichiro James Kazama
Publikationsdatum: 27.03.2024
Verlag: Springer Nature Singapore
Erschienen in: Journal of Bone and Mineral Metabolism
Print ISSN: 0914-8779
Elektronische ISSN: 1435-5604
DOI: https://doi.org/10.1007/s00774-024-01500-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen